MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. Show more

1 Casper Street, Danbury, CT, 06810, United States

https://mannkindcorp.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.313B

52 Wk Range

$2.23 - $6.51

Previous Close

$4.11

Open

$4.06

Volume

4,155,480

Day Range

$3.88 - $4.08

Enterprise Value

1.541B

Cash

111.1M

Avg Qtr Burn

-18.37M

Insider Ownership

1.48%

Institutional Own.

58.18%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
FUROSCIX ReadyFlow™ Auto-Injector Injection (furosemide) Details Edema in Adults with Chronic Heart Failure (CHF) or Chronic Kidney Disease (CKD)	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Afrezza® (insulin human) Inhalation Powder Details Type 1 diabetes, Diabetes, Type 2 diabetes	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FUROSCIX (furosemide) Details Heart failure, Chronic kidney disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FUROSCIX (furosemide) Details Chronic kidney disease, Kidney disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Afrezza® (insulin human) Inhalation Powder Details Diabetes, Type 1 diabetes, Type 2 diabetes	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FUROSCIX (furosemide) Details Heart failure	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tyvaso DPI (Treprostinil Technosphere®) (inhaled treprostinil) Details Pulmonary arterial hypertension, Heart disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MNKD 201 (nintedanib DPI) Details Lung disease, Idiopathic pulmonary fibrosis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Afrezza/Insulin Human (No Code) (Inhaled Insulin) Details Gestational Diabetes	Phase 1/2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ralinepag (MNKD-1501) (Prostacyclin Receptor Agonist) Details Progressive Pulmonary Fibrosis	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ralinepag (MNKD-1501) (Prostacyclin Receptor Agonist) Details Pulmonary Hypertension Associated With Interstitial Lung Disease	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ralinepag (MNKD-1501) (Prostacyclin Receptor Agonist) Details Idiopathic Pulmonary Fibrosis	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ralinepag (MNKD-1501) (Prostacyclin Receptor Agonist) Details Pulmonary Arterial Hypertension	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bumetanide (MNKD-701) (Loop Diuretic) Details Edema Associated With Congestive Heart Failure And Chronic Kidney Disease	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Clofazimine inhalation suspension (MNKD 101) Details Nontuberculous mycobacterial lung disease, Lung disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.